Superior innovation designed for women

The movement starts here

Our Mission

Femasys is a biomedical company aiming to meet women’s needs worldwide with a novel suite of product candidates that include minimally invasive, in-office technologies for reproductive health.

Our Focus

Infertility

In the US alone, more than 9 million women struggle with infertility. Despite advancements, there have been no new affordable options for women struggling with infertility in over 30 years.

Permanent birth control

Over 13 million women in the US no longer intend to have children. Surgical tubal ligation has been performed since the 1880’s and remains the only option for women who want permanent birth control.

Clinical-Stage Assets

Our product candidates are designed to provide solutions to meet the needs of women underserved by current options in infertility and permanent birth control. Whether they are trying to conceive or prevent pregnancy, our pipeline may help women move forward in their journey.

Commercial Assets

FemVue® is a diagnostic tool that provides safe and reliable contrast for ultrasound evaluation of the fallopian tubes. FemVue is available for commercial use in the US, Japan, and other major countries.

FemCath™ allows for assessment of the uterine cavity and, when paired with FemVue, selective evaluation of the fallopian tubes.

Press Releases

05/11/2022 16:05:00

Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2022

Read More »

03/25/2022 08:00:00

Femasys Inc. to Participate in the M-Vest 2022 Virtual Growth Conference

Read More »

03/24/2022 16:05:00

Femasys Inc. Announces Financial Results for the Year Ended December 31, 2021

Read More »